Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/24863
Tipo
ArtículoDerechos de autor
Acceso abierto
Colecciones
Metadatos
Mostrar el registro completo del ítem
DYSREGULATED IMMUNE ACTIVATION IN SECOND-LINE HAART HIV+ PATIENTS IS SIMILAR TO THAT OF UNTREATED PATIENTS
Biomarkers
HIV
Cytokines
T cells
Inflammatory diseases
Viral load
Decision trees
Autor
Afiliación
Universidade de Sao Paulo. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto. Ribeirao Preto, SP, Brazil
Universidade de Sao Paulo. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto. Ribeirao Preto, SP, Brazil
Universidade de Sao Paulo. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto. Ribeirao Preto, SP, Brazil
Universidade de Sao Paulo. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto. Ribeirao Preto, SP, Brazil
Universidade de Sao Paulo. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto. Ribeirao Preto, SP, Brazil
Universidade Federal de Uberlandia. Laboratorio de Bioinformatica e Analises Moleculares. Patos de Minas, MG, Brazil
Universidade Federal de Uberlandia. Laboratorio de Bioinformatica e Analises Moleculares. Patos de Minas, MG, Brazil
Universidade de Sao Paulo. Faculdade de Medicina de Ribeirao Preto. Ribeirao Preto, SP, Brazil
Fundação Oswaldo Cruz. Centro de Pesquisas Rene Rachou. Laboratorio de Biomarcadores para Diagnostico e Monitoramento, Belo Horizonte, MG, Brazil
Universidade de Sao Paulo. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto. Ribeirao Preto, SP, Brazil
Universidade de Sao Paulo. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto. Ribeirao Preto, SP, Brazil
Universidade de Sao Paulo. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto. Ribeirao Preto, SP, Brazil
Universidade de Sao Paulo. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto. Ribeirao Preto, SP, Brazil
Universidade de Sao Paulo. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto. Ribeirao Preto, SP, Brazil
Universidade Federal de Uberlandia. Laboratorio de Bioinformatica e Analises Moleculares. Patos de Minas, MG, Brazil
Universidade Federal de Uberlandia. Laboratorio de Bioinformatica e Analises Moleculares. Patos de Minas, MG, Brazil
Universidade de Sao Paulo. Faculdade de Medicina de Ribeirao Preto. Ribeirao Preto, SP, Brazil
Fundação Oswaldo Cruz. Centro de Pesquisas Rene Rachou. Laboratorio de Biomarcadores para Diagnostico e Monitoramento, Belo Horizonte, MG, Brazil
Universidade de Sao Paulo. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto. Ribeirao Preto, SP, Brazil
Resumen en ingles
Background:Successful highly active antiretroviral therapy (HAART) has changed the outcome of AIDS patients worldwide because the complete suppression of viremia improves health and prolongs life expectancy of HIV-1+ patients. However, little attention has been given to the immunological profile of patients under distinct HAART regimens. This work aimed to investigate the differences in the immunological pattern of HIV-1+ patients under the first- or second-line HAART in Brazil.
Methods:CD4+ T cell counts, Viral load, and plasma concentration of sCD14, sCD163, MCP-1, RANTES, IP-10, IL-1β, IL-6, TNF-α, IL-12, IFN-α, IFN-γ, IL-4, IL-5, and IL-10 were assessed for immunological characterization of the following clinical groups: Non-infected individuals (NI; n = 66), HIV-1+ untreated (HIV; n = 46), HIV-1+ treated with first-line HAART (HAART 1; n = 15); and HIV-1+ treated with second-line HAART (HAART 2; n = 15).
Results:We found that the immunological biosignature pattern of HAART 1 is similar to that of NI individuals, especially in patients presenting slow progression of the disease, while patients under HAART 2 remain in a moderate inflammatory state, which is similar to that of untreated HIV patients pattern. Network correlations revealed that differences in IP-10, TNF-α, IL-6, IFN-α, and IL-10 interactions were primordial in HIV disease and treatment. Heat map and decision tree analysis identified that IP-10>TNF-α>IFN-α were the best respective HAART segregation biomarkers.
Conclusion:HIV patients in different HAART regimens develop distinct immunological biosignature, introducing a novel perspective into disease outcome and potential new therapies that consider HAART patients as a heterogeneous group.
Palabras clave en ingles
Highly-active antiretroviral therapyBiomarkers
HIV
Cytokines
T cells
Inflammatory diseases
Viral load
Decision trees
Compartir